Our results indicated that FUNDC2 expression in patients with triple-negative breast cancer was significantly higher than that in patients with luminal subtype breast cancer, and FUNDC2 expression was positively correlated with TNBC progression-free survival (Figure 3C,F). Here, FUNDC2 is linked to breast carcinoma.